Remicade Biosimilar Market 2026 gaining traction with biosimilar adoption

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The Remicade Biosimilar Market Over The 2026–2030 Period?

The remicade biosimilar market has experienced substantial expansion in recent years. It is anticipated to grow from $4.89 billion in 2025 to $5.97 billion in 2026, achieving a compound annual growth rate (CAGR) of 22.2%. This past growth can be attributed to the high cost burden of branded biologics, the patent expiry of remicade, the increasing prevalence of autoimmune diseases, government support for biosimilar approvals, and hospital-driven bulk procurement models.

The remicade biosimilar market is projected to experience substantial expansion in the coming years. This market is anticipated to reach a valuation of $13.31 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 22.2%. Factors contributing to this growth during the forecast period include an increasing need for cost-effective biologic treatments, the expansion of biosimilar product pipelines, escalating healthcare spending in developing nations, greater acceptance among medical professionals and patients, and supportive reimbursement policies. Key trends observed within the forecast period encompass the wider embrace of economical biosimilars, enhanced prescriber trust in infliximab biosimilars, broader applications across various autoimmune conditions, strategic competitive pricing and procurement through tenders, and deeper market penetration in nascent healthcare sectors.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11952&type=smp

What Drivers Are Expected To Influence The Remicade Biosimilar Market During The Forecast Period?

An anticipated increase in autoimmune disease cases is projected to fuel the expansion of the remicade biosimilar market. These conditions involve the immune system erroneously targeting and harming the body’s own tissues and organs. Remicade biosimilars serve as an effective treatment choice for autoimmune diseases, aiding in symptom management and inflammation reduction. An illustrative example from February 2024, sourced from Arthritis Australia (an Australia-based charitable non-profit focused on arthritis and musculoskeletal conditions), indicates that by 2025, an estimated 562,378 Australians will be living with rheumatoid arthritis (RA), making up 14% of the total arthritis population. This figure for RA sufferers is forecast to climb by 33%, reaching approximately 748,721 individuals by 2040. Consequently, the increasing prevalence of autoimmune diseases is acting as a key catalyst for the remicade biosimilar market’s growth.

How Is The Remicade Biosimilar Market Segmented Across Key Categories?

The remicade biosimilar market covered in this report is segmented –

1) By Type: 100mg/10ml, 500mg/50ml

2) By Disease Indication: Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Psoriatic Arthritis, Plaque Psoriasis

3) By Application: Blood Disorders, Oncology Diseases

Which Upcoming Trends Are Expected To Influence The Remicade Biosimilar Market?

Leading companies in the remicade biosimilar market are concentrating on developing innovative solutions, such as subcutaneous formulations, to achieve a competitive edge. Subcutaneous versions of Remicade offer an alternative administration method for autoimmune disease treatment, facilitating self-administration and potentially enhancing patient adherence to therapy. For example, in March 2024, Celltrion, a South Korea-based biopharmaceutical company, introduced Zymfentra, a biosimilar to Remicade (infliximab), priced at $6,181.08 for two doses over four weeks. This product received FDA approval as the first subcutaneous infliximab formulation for maintaining therapy in adults with moderate-to-severe ulcerative colitis and Crohn’s disease. Eligible commercially insured patients can receive copay assistance of $5 per month, while uninsured or underinsured patients might obtain Zymfentra at no cost.

Who Are The Dominant Players Shaping The Remicade Biosimilar Market Landscape?

Major companies operating in the remicade biosimilar market are Novartis AG, Amgen Inc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., LG Chem Ltd., Nippon Kayaku Co. Ltd., Celltrion Inc., Nichi-iko Pharmaceutical Co. Ltd., Biocon Limited, Alvotech S.A., MabPharm Ltd., Genor Biopharma Co. Ltd, Shanghai Biomabs Pharmaceuticals Co. Ltd., Samsung Bioepis Co. Ltd., Biocad Biopharmaceutical Co, EPIRUS Biopharmaceuticals Inc., BioXpress Therapeutics SA, Mabion S.A

Read the full remicade biosimilar market report here:

https://www.thebusinessresearchcompany.com/report/remicade-biosimilar-global-market-report

Which Region Is Forecast To Lead The Remicade Biosimilar Market In Terms Of Market Size?

Europe was the largest region in the remicade biosimilar market in 2025. The regions covered in the remicade biosimilar market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Remicade Biosimilar Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=11952&type=smp

Browse Through More Reports Similar to the Global Remicade Biosimilar Market 2026, By The Business Research Company

Remicade Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/remicade-biosimilar-global-market-report

Biotechnology Reagents Market Report 2026

https://www.thebusinessresearchcompany.com/report/biotechnology-reagents-global-market-report

Bevacizumab Biosimilars Market Report 2026

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795